1469 Hepatic artery pressure enabled drug delivery (PEDD) of nelitolimod combined with checkpoint inhibition (ICI) in uveal melanoma liver metastases (UM-LM) in ICI-naïve and -refractory patients (pts)
Authors
Rahul A. Sheth (ORCID: https://orcid.org/0000-0001-9615-8985)
Kamaneh Montazeri
Wayne L. Monsky (ORCID: https://orcid.org/0000-0003-0694-6502)
L. Thornton (ORCID: https://orcid.org/0000-0003-1539-4244)
1469 Hepatic artery pressure enabled drug delivery (PEDD) of nelitolimod combined with checkpoint inhibition (ICI) in uveal melanoma liver metastases (UM-LM) in ICI-naïve and -refractory patients (pts)
Rahul A. Sheth, Kamaneh Montazeri, Wayne L. Monsky, L. Thornton et al.
Topics
Ocular Oncology and Treatments
article
1469 Hepatic artery pressure enabled drug delivery (PEDD) of nelitolimod combined with checkpoint inhibition (ICI) in uveal melanoma liver metastases (UM-LM) in ICI-naïve and -refractory patients (pts)
Rahul A. Sheth, Kamaneh Montazeri, Wayne L. Monsky, L. Thornton, Diwakar Davar, J. Kuban, Marlana Orloff, Shailender Bhatia, Sapna Pradyuman Patel, Bartosz Chmielowski, Steven C. Katz, Jose Lutzky, Eric Wehrenberg-Klee, Cara Haymaker, David A. Geller, Prajna Guha, Paula M. Novelli, Bryan D. Cox, Jason LaPorte, Ashley Moody, Richard D. Carvajal, Ann-Marie Hulstine, Shaheer Khan, Sunil Reddy
article en
Abstract
No abstract available for this paper.
Institutions
Northwell Health (US), Cancer Prevention Institute of California (US), Roger Williams Medical Center (US), The University of Texas MD Anderson Cancer Center (US), University of Miami (US), University of California, Los Angeles (US), Providence College (US), University of Washington (US), Thomas Jefferson University Hospital (US), Massachusetts General Hospital (US), UPMC Hillman Cancer Center (US), Salus (United States) (US), Sylvester Comprehensive Cancer Center (US), US Biologic (United States) (US), Stanford Cancer Institute, University of Houston (US)